HERB: Single-Arm Phase II Trial of Trastuzumab Deruxtecan for Unresectable or Recurrent HER2-Expressing Biliary Tract Cancers

June 3-7, 2022; Chicago, Illinois
Single-arm study shows preliminary activity of trastuzumab deruxtecan in advanced HER2-positive biliary tract cancers, including for HER2-low disease.
Format: Microsoft PowerPoint (.ppt)
File Size: 165 KB
Released: June 9, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo, Inc.

Related Content

Nina Beri, MD reviews ongoing clinical trials in targeted therapies for patients with cholangiocarcinoma presented at ASCO 2022, from Clinical Care Options (CCO)

person default Nina Beri, MD Released: August 3, 2022

Downloadable slideset on therapies for previously treated advanced HER2-negative gastric/GEJ cancers, from Clinical Care Options (CCO)

Samuel Klempner, MD Released: July 21, 2022

Data on dostarlimab for locally advanced, mismatch repair-deficient rectal cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 14, 2022

Expanded results from CheckMate 648 of first-line nivolumab + chemotherapy or ipilimumab vs chemotherapy alone in advanced esophageal squamous cell cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 13, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings